COREMEDIC GMBH
An innovative cardiology company
CoreMedic is dedicated to developing solutions for the largest underserved need in structural heart disease. Headquartered in Radolfzell am Bodensee, Germany, our mission is to transform established surgical reconstruction principles into standardized, transcatheter therapies for mitral regurgitation.
01
The Beginning
CoreMedic was initiated in 2012 as a spin-out in Bern, Switzerland, in order to develop an innovative treatment concept for mitral valve regurgitation (MR). The initiators of CoreMedic had a simple but challenging idea: to combine the least invasive treatment option for MR, replacement of mitral chords, and the least invasive operational procedure into one new system: ChordArt.
02
Independence
In 2014, CoreMedic became operational as an independent entity with its own management and facilities.
03
Human Trial
In 2017, the development of ChordArt had progressed towards first use in a human trial, enabling CoreMedic to attract institutional financing. The company moved to the RIZ innovation center in Radolfzell, Germany, located at Lake Constance close to the Swiss border within the leading medical technology cluster of Tuttlingen, Germany.
04
Success
Following the successful conclusion of the first human trial of ChordArt in 2018, and five-year data confirming the powerful treatment effect of the ChordArt implant in patients with severe MR, CoreMedic GmbH is tirelessly working to make the ChordArt TMVr System available to patients.
ABOUT US
CoreMedic is an innovative medical device company dedicated to addressing the largest underserved need in cardiology. By transforming established surgical reconstruction techniques into minimally invasive transcatheter therapies, we are expanding treatment options for mitral valve disease patients worldwide.
WHY CHORDART?
Surgical-Quality Repair. Minimal Footprint.
The ChordArt system is a biomimetic implant designed to replace compromised chords while reflecting individual patient anatomy. Unlike other interventions, it preserves anatomical integrity without precluding future therapeutic options.
01
Preserves Natural Anatomy
The implant utilizes anchor points identical to natural chords (leaflet and papillary muscle). This robust, solid design ensures minimal surface exposure while restoring physiological function.
02
Proven 5-Year Efficacy
The therapeutic effect of chordal replacement is established by decades of surgical evidence. The ChordArt implant is further validated by 5-year clinical data demonstrating safe, long-term reduction of mitral regurgitation.
03
Reliable, Standardized Delivery
ChordArt transforms established surgical reconstruction principles into a safe, 5-step transcatheter (TMVr) procedure, requiring no intraoperative length adjustments or tensioning of the leaflet.
THE CHORDART ADVANTAGE
Patient-Specific Fit
Chord length is predetermined during echocardiographic examination, eliminating the need for intraoperative length adjustments.
Anatomical Anchoring
Utilizes anchor points identical to natural chords—both on the leaflet and papillary muscle—resulting in minimal surface exposure.
Robust Design
Features a solid, reliable biomimetic structure that preserves future therapeutic options for the patient.
